CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

92Bio revives a T cell engager it had transferred to Amgen

Positive
AI Analysis

Summary

92Bio is reviving a T cell engager therapeutic that it originally developed and had previously transferred to Amgen. The California startup is taking back control of the program from Amgen.

Importance:4/10
Sentiment:
0.30
T cell engagerdrug revivallicensingimmunotherapy
Related Companies

Read the original article

Published by Endpoints News on July 1, 2026 1:30 PM

Read Original